TAM Stock Screener – Stocks Appearing In Buffett, Greenblatt, Simons Portfolios

Johnny HopkinsStock ScreenerLeave a Comment

Part of the weekly research here at The Acquirer’s Multiple features some of the top picks from our Stock Screeners and some top investors who are holding these same picks in their portfolios. Investors such as Warren Buffett, Joel Greenblatt, Carl Icahn, Jim Simons, Prem Watsa, Jeremy Grantham, Seth Klarman, Ray Dalio, and Howard Marks. The top investor data is provided from their latest 13F’s. This week we’ll take a look at:

Biogen Inc (NASDAQ: BIIB)

Biogen and Idec merged in 2003, combining forces to market Biogen’s multiple sclerosis drug Avonex and Idec’s cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen’s MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis.

A quick look at the price chart below for Biogen shows us that the stock is down 1.48% in the past twelve months. We currently have the stock trading on an Acquirer’s Multiple of 6.09, which means that it’s undervalued.

(Source: Morningstar)

Superinvestors who currently hold positions in Biogen include:

Jim Simons – 4,473,912 shares

Cliff Asness – 2,120,127 shares

Warren Buffett – 643,022 shares

Ken Griffin – 212,903 shares

Joel Greenblatt – 133,975 shares

Ken Fisher – 93,625 shares

Rich Pzena – 47,151 shares

Paul Tudor Jones – 4,338 shares

Murray Stahl – 4,124 shares

For more articles like this, check out our recent articles here.

FREE Stock Screener

Don’t forget to check out our FREE Large Cap 1000 – Stock Screener, here at The Acquirer’s Multiple:

unlimited

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.